Ventricular tachycardia-based long QT without hypocalcaemia after use of ibandronic acid.
Many drugs are known to cause lengthening of the QT interval. Ibandronic acid is a frequently used agent in the treatment of osteoporosis and is known to cause prolongation of the QT interval due to hypocalcaemia. However, no cases of long QT syndrome associated with ventricular tachycardia (VT) with a serum calcium level within the normal limits have been reported in the literature. We report on a case of a VT-based long QT syndrome associated with the use of ibandronic acid.
Department of Cardiology, Medical Faculty, Pamukkale University, Denizli, Turkey.
Yusuf Izzettin
YI
Alihanoglu
Burcu
B
Uludag
Ismail Dogu
ID
Kilic
Ufuk
U
Eryilmaz
Harun
H
Evrengul
D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D004452:Echocardiography; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D006352:Heart Ventricles / Q000000981:diagnostic imaging / Q000473:pathology*; D006801:Humans; D006996:Hypocalcemia; D000077557:Ibandronic Acid; D008875:Middle Aged; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy*; D020127:Recovery of Function; D017180:Tachycardia, Ventricular / Q000150:complications / Q000175:diagnosis*; D014262:Tricuspid Valve Insufficiency / Q000175:diagnosis* / Q000209:etiology; D028761:Withholding Treatment
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077557:Ibandronic Acid